Mineralocorticoid receptor overactivation: novel approach to treatment of multi-organ impact with finerenone

Thursday, 22 September 2022, 08:30 - 10:00, Jacobsohn Hall

Per-Henrik Groop, Finland: Welcome and introduction

Luiza Caramori; USA: MR overactivation: targeting systemic impact with non-steroidal MRA

Janet McGill, USA: FIDELITY: Cardiorenal outcomes across the whole spectrum of CKD in type 2 diabetes

Peter Rossing, Denmark: Key subgroup analyses from the trial programme

Andreas L Birkenfeld, Germany: Safety and considerations for optimising patient outcomes

Jennifer B Green, USA / Hiddo J Lambers Heerspink, Netherlands: Clinical consequences from FIDELITY and horizons of the FINEOVATE program

Q&A and group discussion